KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV) from a hold rating to a buy rating in a research note published on Saturday morning.

Other equities research analysts have also recently issued research reports about the company. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC raised their target price on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. HC Wainwright lifted their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Citizens Jmp reduced their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. Finally, Stifel Nicolaus increased their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.60.

KalVista Pharmaceuticals Stock Down 5.0%

KalVista Pharmaceuticals stock opened at $18.36 on Friday. KalVista Pharmaceuticals has a fifty-two week low of $9.23 and a fifty-two week high of $19.95. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market capitalization of $940.40 million, a P/E ratio of -4.65 and a beta of -0.35. The stock has a 50-day simple moving average of $16.12 and a 200-day simple moving average of $14.47.

Insider Activity at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par sold 39,986 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Thursday, March 26th. The stock was sold at an average price of $18.28, for a total value of $730,944.08. Following the transaction, the insider directly owned 5,089,354 shares in the company, valued at approximately $93,033,391.12. This trade represents a 0.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brian Piekos sold 1,767 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the transaction, the chief financial officer directly owned 13,762 shares in the company, valued at approximately $214,274.34. The trade was a 11.38% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 248,009 shares of company stock worth $4,213,467 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of KALV. Vanguard Group Inc. increased its stake in KalVista Pharmaceuticals by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after buying an additional 88,720 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of KalVista Pharmaceuticals in the 3rd quarter worth $24,360,000. State Street Corp lifted its stake in shares of KalVista Pharmaceuticals by 21.3% in the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock worth $30,874,000 after acquiring an additional 336,195 shares during the period. Vestal Point Capital LP boosted its holdings in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after acquiring an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC boosted its holdings in shares of KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.